The Potential Role of The Nuclear Factor Erythroid 2–Related Factor 2 Depletion on Gonadotropin-Releasing Hormone Imbalance in Polycystic Ovarian Syndrome Iraqi Patients
The nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of most cytoprotective genes that respond to oxidative stresses. Thus, Nrf2 depletion is usually associated with excessive oxidative stress (OS). We sought to assess Nrf2 concentration as an indicator of elevated OS in wom...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bogor Agricultural University
2025-07-01
|
| Series: | Hayati Journal of Biosciences |
| Online Access: | https://journal.ipb.ac.id/index.php/hayati/article/view/62649 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of most cytoprotective genes that respond to oxidative stresses. Thus, Nrf2 depletion is usually associated with excessive oxidative stress (OS). We sought to assess Nrf2 concentration as an indicator of elevated OS in women with PCOS. Likewise, study the effects associated with this depletion on the balance of gonadotropin-releasing hormone (GnRH). The case-control study comprised ninety women of reproductive age. Our results revealed that women with PCOS had significantly higher blood Nrf2 depletion compared with the non-PCOS group (P = 0.000). So, there was a significant increase in both Luteinizing hormone (LH) concentration and LH\FSH ratio (P = 0.000 and P = 0.007, respectively. In the PCOS group, Nrf2 depletion was adversely correlated with elevated LH level (-0.551) at (P = 0.012), and elevated LH\FSH ratio (-0.628) at (P = 0.003), infertility (-0.460) at (p = 0.041) and menstrual irregularity (-0.575) at (P = 0.008). Meantime, according to the odds ratio analysis, Nrf2 depletion had a high relative risk in the etiology of syndrome 0.967 (0.932–0.945) at (P = 0.048). In conclusion, Nrf2 depletion had a role in the GnRH imbalance in PCOS through several mechanisms. Thus, we can suggest that enhancing the Nrf2 pathway can be a possible therapeutic approach for PCOS treatment.
|
|---|---|
| ISSN: | 1978-3019 2086-4094 |